Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

interferon-free, all-oral regimens for previously treated and treatment-naive patients with HCV," said Jay Luly, Ph.D., President and CEO of Enanta.  "Enanta's involvement in five distinct HCV drug classes provides multiple avenues to pursue our goal of bringing to patients innovative therapies that are safer and more effective than current treatments."

Oral Presentations

Oral Presentation, Eric Lawitz et al.; Thursday, April 19, 16:00-18:00 CET / 10:00 am - 12:00 pm EDT.
A 12-week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naive HCV IL28B-CC Genotype-1-Infected Subjects

  • The objectives of the 12-week, phase 2 study were to assess the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450/r 150/100 mg QD and ABT-072 400 mg QD + ribavirin administered for 12 weeks.
  • The study was conducted in 11 treatment naive adults from multiple ethnic backgrounds with non-cirrhotic HCV GT1 (8 GT 1a, 3 GT 1b). Ribavirin 1000-1200 mg/day was weight-based and dosed twice daily.
  • The primary endpoint was percentage of patients with HCV RNA <25 IU/ml from week 4 through 12. Other trial endpoints include early virologic response, RVR and SVR through 24 weeks.
  • 100 percent of patients maintained HCV RNA levels <25 IU/mL from weeks 4 through 12 of treatment, and all had undetectable HCV RNA from week 5 to the end of treatment.
  • 91 percent of patients achieved SVR24,
  • In the trial, the most common adverse events reported were headache, fatigue, nausea and dry skin. There were no premature discontinuations.

Late-Breaking Oral Presentation, Fred Poordad, et al.; Saturday, April 21, 15:30-17:
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... SIPP International Industries Inc. (OTCBB: SIPN), ... hospitality and medical technology industries announced today that they ... Japanese Consulting firm based in Osaka Japan. Upon completion ... residual revenues within three months.  FVJ ...
... Jan. 17, 2012 Bayer HealthCare today announced latest ... the Phase III CORRECT ( Co lo r ectal ... ebo after failure of standard t herapy) trial. ... improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
(Date:7/30/2014)... 2014 The family of a Vermont ... a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his ... LLP reports. According to the complaint, which was filed ... on July 25th, the decedent had been taking Xarelto ... brain bleed that ultimately led to his death on ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 Frozen ... Women are more likely to develop this nasty condition which ... and 60, and can last up to two and half ... known as frozen shoulder, and with good reason: it can ... your shirt — that is, if you aren't in too ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... a PET scan may interfere with the results seen, says ... emission tomography (PET) or computed tomography (CT) scan is done ... evaluate the effect of treatment on an already diagnosed malignant ... in the body that can be traced with the help ...
... have reportedly succeeded in generating sperm// and ovarian cells ... for Stem Cell Biology in Sheffield said that "the ... sperm and eggs to use in assisted conception treatments". ... with infertility. This research will allow embryonic stem cells ...
... processed meat can increase your chance of having colorectal ... the National Cancer Institute. ,Colon and rectum together ... cancer is also called colorectal cancer. Cancer of the ... malignant cells within the lining of colon or rectum. ...
... in schizophrenic patients with the help of seroquel ... is a chronic severe disabling mental illness. Some ... seen or heard, feelings of being persecuted, becoming ... symptomatically, but only one in five patients have ...
... Researchers had been able to find out why the diabetes ... University of Utah had found that the drug TZDs activates ... This is situated in the collecting duct of the kidney. ... in the body and causes edema. ,TZD drugs are ...
... inflammations of the gum may increase the risk of ... early in life. ,According to a research study ... Conference on Prevention of Dementia held in US, periodontal ... people. ,Alzheimer’s disease affects the brain cells and ...
Cached Medicine News:
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
Calcitonin RIA Kit...
... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: